13F filings

Baker Bros. Advisors

Its 13F for Q2 2026, filed Aug 14, 2026.

Julian & Felix BakerThe filing on EDGAR

Share
Download on the App StoreGet it on Google Play

Free on iOS and Android

Scan to get
the app

Biggest moves

Q2 2026, quarter ended Jun 30

Baker Bros. added $353.6M of Revolution Medicines in Q2 2026.

Shares up 20%. The stake was $2.1B at Jun 30.

RVMD Revolution Medicines+$353.6M
INSM Insmed+$146.6M
EWTX Edgewise Therapeutics−$116.8M
ABVX Abivax, sold out−$97.5M
SYRE Spyre Therapeutics, sold out−$50.4M
IDYA IDEAYA Biosciences+$39.6M
SNSE Faeth Therapeutics, new+$32.2M
RLAY Relay Therapeutics+$31.2M
CNTA Centessa Pharmaceuticals, sold out−$26.6M

13F value

Held on Jun 30, 2026
$20.0B

in 84 positions.

Sector mix by disclosed value

  • Healthcare99.7%
Q1 2026 filing$17.4B
Q2 2026 filing$20.0B

+14.6% filing to filing, from price moves and buying or selling: not the fund’s return. Not investment advice.

GetSignal estimate

Two figures, two sources

Assets under management, as reported to the SEC

$28.1B

Regulatory assets under management on Form ADV, filed Mar 27, 2026 by Baker Bros. Advisors LP. A gross figure: it counts borrowed money and assets a 13F never lists, so it is not the 13F value.

13F stock positions at the latest close

$21.7B

+9.2% on the $19.9B of stock lines filed for Jun 30

If unchanged since Jun 30, 2026: the filing's stock lines at the Nov 12 close. Options and bonds left out; 99.4% of the value priced, the rest carried at its filed value. An estimate of what the filed positions are worth now, not a forecast and not the fund's return. How it is made. Not investment advice.

New positions

Q2 2026 13F

Faeth Therapeutics is the one new position among the 15 largest moves. Worth $32.2M at Jun 30.

Sold out

Q2 2026 13F
6

positions sold out among the 15 largest moves. Worth $233.7M together at Mar 31, the quarter before.

ABVXAbivax$97.5M
SYRESpyre Therapeutics$50.4M
CNTACentessa Pharmaceuticals$26.6M
IMCRImmunocore Holdings$22.1M
CTNMContineum Therapeutics$18.6M

Largest holdings

50 largest of 84 positions

Incyte is the largest, at 17.5% of the 13F value. The five largest are 52.0%.

HoldingTypeValueShares% of 13F value
INCYIncyteShares$3.5B30,762,330 shares17.5%
ONCBeOne Medicines AGShares$2.5B8,801,567 shares12.6%
RVMDRevolution MedicinesShares$2.1B11,443,357 shares10.7%
MDGLMadrigal PharmaceuticalsShares$1.2B2,143,131 shares5.8%
ACADAcadia PharmaceuticalsShares$1.1B42,912,904 shares5.4%
KYMRKymera TherapeuticsShares$992.7M8,657,242 shares5.0%
INSMInsmedShares$937.8M8,796,111 shares4.7%
CELCCelcuityShares$828.2M7,915,792 shares4.2%
KODKodiak SciencesShares$776.1M19,919,186 shares3.9%
RYTMRhythm PharmaceuticalsShares$622.3M5,604,483 shares3.1%
PRAXPraxis Precision MedicinesShares$587.0M1,753,198 shares2.9%
ALKSAlkermesShares$524.6M10,012,267 shares2.6%
SMMTSummit TherapeuticsShares$477.7M32,786,348 shares2.4%
GRALGRAILShares$275.0M4,028,614 shares1.4%
ABCLAbCellera BiologicsShares$259.1M33,012,138 shares1.3%
IMVTImmunovantShares$209.4M5,435,220 shares1.0%
IDYAIDEAYA BiosciencesShares$186.7M5,010,030 shares0.9%
KNSAKiniksa Pharmaceuticals InternationalShares$181.3M2,834,643 shares0.9%
ROIVRoivant SciencesShares$166.9M4,716,831 shares0.8%
ARWRArrowhead PharmaceuticalsShares$162.4M1,992,783 shares0.8%
IONSIonis PharmaceuticalsShares$162.4M2,047,727 shares0.8%
EWTXEdgewise TherapeuticsShares$150.4M3,701,719 shares0.8%
REPLReplimune GroupShares$122.3M11,045,336 shares0.6%
NRIXNurix TherapeuticsShares$113.0M4,658,556 shares0.6%
STOKStoke TherapeuticsShares$109.2M3,336,697 shares0.5%
GLUEMonte Rosa TherapeuticsShares$105.2M4,345,736 shares0.5%
IMTXImmaticsShares$96.3M9,508,565 shares0.5%
DNLIDenali TherapeuticsShares$96.0M3,734,336 shares0.5%
CRNXCrinetics PharmaceuticalsShares$88.0M2,351,465 shares0.4%
DNTHDianthus TherapeuticsShares$83.1M852,164 shares0.4%
GPCRStructure TherapeuticsShares$76.9M1,432,529 shares0.4%
CelcuityNote$69.2Mn/a0.3%
RAPPRapport TherapeuticsShares$64.5M1,547,090 shares0.3%
ALMSAlumisShares$56.6M2,012,500 shares0.3%
PRLDPrelude TherapeuticsShares$54.0M10,123,824 shares0.3%
RLAYRelay TherapeuticsShares$52.9M2,826,783 shares0.3%
MIRMMirum PharmaceuticalsShares$52.2M445,975 shares0.3%
BCYCBicycle TherapeuticsShares$46.2M10,885,357 shares0.2%
ELVNEnliven TherapeuticsShares$45.9M905,191 shares0.2%
CLDXCelldex TherapeuticsShares$44.0M1,182,611 shares0.2%
VRDNViridian TherapeuticsShares$43.8M2,383,025 shares0.2%
DSGNDesign TherapeuticsShares$38.8M2,678,430 shares0.2%
TRDAEntrada TherapeuticsShares$37.3M5,072,730 shares0.2%
SNSEFaeth TherapeuticsShares$32.2M1,286,411 shares0.2%
AKTSAktis OncologyShares$32.1M996,351 shares0.2%
NGNENeurogeneShares$31.2M991,691 shares0.2%
JBIOJade BiosciencesShares$27.3M1,230,426 shares0.1%
TSHATaysha Gene TherapiesShares$27.3M4,004,756 shares0.1%
RCUSArcus BiosciencesShares$26.0M844,816 shares0.1%
IRONDisc MedicineShares$25.6M349,657 shares0.1%

% of 13F value is the position's value against the whole disclosed 13F value, so the rows shown here do not sum to 100% unless every position is listed. A Note is a convertible bond, which the filing sizes by its face amount rather than a share count.

13F moves15 largest moves, line by line

What Baker Bros. Advisors bought and sold in Q2 2026

Each filed line against the Q1 2026 filing.
HoldingMoveShare changeEst. amount movedValue after
RVMDRevolution MedicinesAdded+19.8%+$353.6M$2.1B after
INSMInsmedAdded+18.5%+$146.6M$937.8M after
EWTXEdgewise TherapeuticsTrimmed-43.7%-$116.8M$150.4M after
ABVXAbivaxExited-100%-$97.5M$0 after
SMMTSummit TherapeuticsTrimmed-9.9%-$52.5M$477.7M after
SYRESpyre TherapeuticsExited-100%-$50.4M$0 after
IDYAIDEAYA BiosciencesAdded+26.9%+$39.6M$186.7M after
SNSEFaeth TherapeuticsNewnew+$32.2M$32.2M after
RLAYRelay TherapeuticsAdded+143.7%+$31.2M$52.9M after
CNTACentessa PharmaceuticalsExited-100%-$26.6M$0 after
IMCRImmunocore HoldingsExited-100%-$22.1M$0 after
ABCLAbCellera BiologicsAdded+9.0%+$21.5M$259.1M after
CLDXCelldex TherapeuticsAdded+77.7%+$19.2M$44.0M after
CTNMContineum TherapeuticsExited-100%-$18.6M$0 after
ARGXargenx SEExited-100%-$18.4M$0 after

A change is this filing measured against the one before it. Est. amount moved is the shares added or sold, priced at the Jun 30, 2026 close. An estimate: a 13F gives no trade prices or dates. For a sold-out position, its value at the previous quarter end.

Source: Form 13F, filed with the SEC on Aug 14, 2026, for positions held on Jun 30, 2026. A 13F lists US-listed stock and options at their quarter-end value; short sales, cash and most bonds are not in it. Methodology · Guide to Form 13F. Checked for newer filings on Nov 14, 2026. Not investment advice.

Questions

What Baker Bros. Advisors holds, what moved and how current the filing is.

What does Baker Bros. Advisors hold?

Baker Bros. Advisors disclosed 84 positions worth $20.0B in the Q2 2026 13F filing. The largest is INCY at 17.5% of the disclosed value. A 13F lists US-listed stock and options on it; short sales and cash are not in it.

What did Baker Bros. Advisors buy and sell last quarter?

Comparing the Q2 2026 filing with the quarter before, the largest moves were adding to RVMD, adding to INSM, trimming EWTX and selling out of ABVX. Changes are measured against the previous filing, not against trades, because a 13F does not disclose trades.

How current is this?

This is the Q2 2026 filing, covering positions held on Jun 30, 2026 and filed with the SEC on Aug 14, 2026. A 13F is due 45 days after the quarter ends, so the most recent filing is always at least six weeks behind the market, and the manager may have changed the book since.

Other managers we track

ranked by stock held
See every manager we track